FILTER
LATEST ARTICLES
Made in Turkey: The localization policy and its effects
February 12, 2020
Localisation efforts are shaping the dynamics between local and foreign companies.
The World’s Pharmacy: India’s Generic Drug Industry
February 12, 2020
India must adapt to maintain its position as the world’s largest supplier of generic drugs.
A West-Meets-East Of The Pharma Industry
January 31, 2020
Portrait of the Turkey Pharmaceuticals industry.
The 2020s: India’s decade?
November 19, 2019
As 2020 approaches, GBR takes a look at how far India has come to achieving its Pharma Vision 2020
Chile: Uncertainty Hits the Stalwart of Latin American Mining
November 12, 2019
Social turmoil returns to the streets of Santiago after 30 years of calm.
Ghana’s Push Towards Modernization and Innovation
November 12, 2019
Ghana must adapt to maintain its new title of the top gold producer in Africa.
An Industry in Decline: Understanding the Politics behind South Africa’s Downfall
October 02, 2019
Once the mining capital of Africa, South Africa’s decline in regional hegemony is inextricably linked to its fraught sociopolitical fabric.
Peru’s Junior Segment
September 10, 2019
Juniors have good projects to work on, but continue to suffer costly delays to obtain government permits.
Production and Exploration Highlights from the DRC
September 10, 2019
Copper, cobalt and lithium continue to rule the day in the heart of Africa.
U.S. Pharmaceuticals: The East Coast
July 25, 2019
From New England to the Mid-Atlantic, a rising tide lifts all boats across the biopharma value chain.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
